# CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study

> **NCT05666700** · PHASE1 · RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 10 (estimated)

## Conditions studied

- Extramedullary Myeloma

## Interventions

- **BIOLOGICAL:** Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent

## Key facts

- **NCT ID:** NCT05666700
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-08
- **Primary completion:** 2026-01
- **Final completion:** 2027-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05666700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05666700, "CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05666700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*